Expert Video - What targeted therapies are used for people with the ROS1 mutation?
Dr. Robert Winn, cancer expert, describes the potential of crizotinib as a targeted therapy for people with ROS1 mutations in non-small-cell lung cancer, and how the health care team can help reduce and relieve side effects of this and other targeted therapies.
Share with family and friends:
Click here to take our SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.
This educational activity has been developed by
A Breath of Hope Lung Foundation and Mechanisms in Medicine Inc.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Foundation Inc., Bristol-Myers Squibb Grants and Giving, Foundation Medicine, Genentech, Merck Sharp & Dohme LLC , Neogenomics, Novartis, and Pfizer.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.